Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
Moderna (NASDAQ: MRNA) has announced its upcoming participation in Bernstein's 41st Annual Strategic Decisions Conference (SDC). The presentation is scheduled for Thursday, May 29th, 2025, at 10:00 AM ET. Investors and interested parties can access a live webcast of the presentation through the "Events and Presentations" section on Moderna's investor website at investors.modernatx.com. The webcast recording will remain available on the company's website for a minimum of 30 days after the presentation.
Moderna (NASDAQ: MRNA) ha annunciato la sua prossima partecipazione al 41° Annuale Bernstein Strategic Decisions Conference (SDC). La presentazione è prevista per giovedì 29 maggio 2025 alle 10:00 ET. Investitori e interessati potranno seguire la diretta streaming della presentazione nella sezione "Eventi e Presentazioni" del sito dedicato agli investitori di Moderna, disponibile su investors.modernatx.com. La registrazione del webcast resterà disponibile sul sito aziendale per almeno 30 giorni dopo l’evento.
Moderna (NASDAQ: MRNA) ha anunciado su próxima participación en la 41ª Conferencia Anual de Decisiones Estratégicas de Bernstein (SDC). La presentación está programada para el jueves 29 de mayo de 2025 a las 10:00 AM ET. Inversores y personas interesadas podrán acceder a la transmisión en vivo a través de la sección "Eventos y Presentaciones" en el sitio web para inversores de Moderna en investors.modernatx.com. La grabación del webcast estará disponible en la página web de la compañía durante al menos 30 días después de la presentación.
Moderna (NASDAQ: MRNA)가 Bernstein의 제41회 연례 전략적 결정 회의(SDC)에 참여할 예정임을 발표했습니다. 발표는 2025년 5월 29일 목요일 오전 10시(동부시간)에 예정되어 있습니다. 투자자 및 관심 있는 분들은 Moderna 투자자 웹사이트의 "이벤트 및 발표" 섹션에서 발표를 실시간 웹캐스트로 시청할 수 있습니다(주소: investors.modernatx.com). 웹캐스트 녹화는 발표 후 최소 30일 동안 회사 웹사이트에서 시청 가능합니다.
Moderna (NASDAQ : MRNA) a annoncé sa prochaine participation à la 41e conférence annuelle Bernstein sur les décisions stratégiques (SDC). La présentation est prévue pour le jeudi 29 mai 2025 à 10h00 ET. Les investisseurs et les parties intéressées pourront accéder à une diffusion en direct via la section "Événements et Présentations" du site destiné aux investisseurs de Moderna à l'adresse investors.modernatx.com. L'enregistrement du webcast restera disponible sur le site de la société pendant au moins 30 jours après la présentation.
Moderna (NASDAQ: MRNA) hat seine bevorstehende Teilnahme an der 41. Bernstein Annual Strategic Decisions Conference (SDC) angekündigt. Die Präsentation ist für Donnerstag, den 29. Mai 2025, um 10:00 Uhr ET geplant. Investoren und Interessierte können die Präsentation live über den Bereich "Events and Presentations" auf der Investorenseite von Moderna unter investors.modernatx.com verfolgen. Die Aufzeichnung des Webcasts wird mindestens 30 Tage nach der Präsentation auf der Website des Unternehmens verfügbar bleiben.
- None.
- None.
CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:
Bernstein's 41st Annual Strategic Decisions Conference (SDC), on Thursday, May 29th at 10:00am ET
A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website.
A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
FAQ
When is Moderna presenting at Bernstein's Strategic Decisions Conference 2025?
How can I watch Moderna's presentation at the Bernstein Conference?
How long will Moderna's Bernstein Conference presentation replay be available?
What is the website address for Moderna's investor relations?
